Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Equity: 2013-2025

Historic Return on Equity for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to -1.14%.

  • Enanta Pharmaceuticals' Return on Equity fell 30.00% to -1.14% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.14%, marking a year-over-year decrease of 30.00%. This contributed to the annual value of -0.85% for FY2025, which is 17.00% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Return on Equity stood at -1.14% for Q3 2025, which was down 6.89% from -1.06% recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Return on Equity high stood at -0.20% for Q1 2021, and its period low was -1.14% during Q3 2025.
  • Its 3-year average for Return on Equity is -0.78%, with a median of -0.74% in 2024.
  • Data for Enanta Pharmaceuticals' Return on Equity shows a maximum YoY crashed of 33bps (in 2025) over the last 5 years.
  • Over the past 5 years, Enanta Pharmaceuticals' Return on Equity (Quarterly) stood at -0.29% in 2021, then dropped by 9bps to -0.39% in 2022, then fell by 29bps to -0.68% in 2023, then dropped by 19bps to -0.87% in 2024, then fell by 30bps to -1.14% in 2025.
  • Its last three reported values are -1.14% in Q3 2025, -1.06% for Q2 2025, and -0.94% during Q1 2025.